Physician profile
John Hammonds
NPI 1518494020
$3,740.84
in general payments reported to CMS, 2019-2025
31 companies · $919 in 2025
The $919 reported for 2025 was more than what 85% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $1,246 · 2023: $554 · 2024: $580 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $627.97 | 2021-2025 | General - Pain Management |
| Collegium Pharmaceutical, INC. | $500.39 | 2022-2025 | Belbuca, Xtampza |
| Nevro Corp. | $465.39 | 2022-2024 | Senza |
| Globus Medical, INC. | $371.21 | 2025 | Senza |
| Abbott Laboratories | $262.48 | 2022-2025 | Proclaim |
| Abbvie INC. | $250.69 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.33 | 2022-2025 | Relistor |
| Medtronic, INC. | $118.64 | 2022-2023 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Hikma Pharmaceuticals USA | $112.61 | 2022 | |
| Scilex Pharmaceuticals INC. | $104.87 | 2022-2025 | Ztlido |
| Amgen INC. | $81.69 | 2021-2022 | |
| Mml US, INC. | $77.60 | 2025 | Reactiv8 |
| Nalu Medical, INC. | $67.80 | 2022-2023 | Nalu Neurostimulation System |
| Novo Nordisk INC | $58.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $57.90 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $55.74 | 2023-2024 | |
| Valinor Pharma, LLC | $43.03 | 2023-2024 | Movantik |
| Acadia Pharmaceuticals INC | $40.51 | 2021-2024 | Nuplazid |
| Ferring Pharmaceuticals INC. | $29.07 | 2025 | Euflexxa |
| Kowa Pharmaceuticals America, INC. | $28.42 | 2022-2023 | Seglentis, Livalo |
| Avanos Medical | $22.92 | 2025 | Generator |
| Axsome Therapeutics, INC. | $22.87 | 2025 | Symbravo |
| Atland Pharmaceuticals, LLC | $22.81 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Vertos Medical, INC. | $22.53 | 2024 | Mild Device Kit |
| Vertex Pharmaceuticals Incorporated | $21.71 | 2025 | |
| Axonics, INC. | $20.52 | 2024 | Axonics |
| Zoll Respicardia, INC. | $19.68 | 2023 | Remede System |
| Bioventus LLC | $19.47 | 2022 | |
| Glaxosmithkline, LLC. | $17.03 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.63 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hammonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.